Cited by 1,216Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid MetabolismLipid metabolism and disorders

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

Open access
Schoonjans, K, Staels, B, Auwerx, J·1996·Journal of Lipid Research

Abstract

The three types of peroxisome proliferator-activated receptors (PPAR), termed alpha, delta (or beta), and gamma, belong to the nuclear receptor superfamily. Although peroxisome proliferators, including fibrates and fatty acids, activate the transcriptional activity of these receptors, only prostaglandin J2 derivatives have been identified as natural ligands of the PPAR gamma subtype that also binds thiazolidinedione antidiabetic agents with high affinity. PPARs heterodimerize with retinoic X receptor (RXR) and alter the transcription of target genes after binding to response elements or PPREs, consisting of a direct repeat of the nuclear receptor hexameric DNA recognition motif (PuGGTCA) spaced by 1 nucleotide (DR-1). Upon activation by fatty acids (FAs) and drugs that affect lipid metabolism, PPARs control the expression of genes implicated in intra- and extracellular lipid metabolism, most notably those involved in peroxisomal beta-oxidation. PPARs partially mediate the inductive effects of fibrates and fatty acids on high density lipoprotein (HDL) cholesterol levels by regulating the transcription of the major HDL apolipoproteins, apoA-I and apoA-II. The hypotriglyceridemic action of fibrates and certain fatty acids also involves PPAR and is constituted of: 1) increased hydrolysis of plasma triglycerides due to induction of LPL and reduction of apoC-III expression; 2) stimulation of cellular fatty acid uptake and conversion to acyl-CoA derivatives due to increased expression of genes for fatty acid transport protein and acyl-CoA synthetase; 3) increased peroxisomal and mitochondrial beta-oxidation; and 4) decreased synthesis of fatty acids and triglycerides and decreased production of very low density lipoprotein (VLDL). Hence, both enhanced catabolism of triglyceride-rich particles and reduced secretion of VLDL particles contribute to the hypolipidemic effect of fibrates and fatty acids. Finally, PPARs appear to be involved in differentiation processes because activation of PPAR gamma 2 triggers adipocyte differentiation and stimulates expression of several genes critical to adipogenesis. It is suggested that PPARs are key messengers responsible for the translation of nutritional and pharmacological stimuli into changes in gene expression and differentiation pathways.

Integrity signals

Registry

Crossref · 10.1016/s0022-2275(20)42003-6

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Even in patients with homozygous familial hypercholesterolemia for whom other drug therapies show no effect, lomitapide decreases the LDL-C level by approximately 50%.

    “Even in patients with homozygous FH (HoHF) for whom other drug therapies show no effect, lomitapide decreases the LDL-C level by approximately 50%.”
  • Four weeks after starting a low-fat diet and lomitapide in patients with homozygous familial hypercholesterolemia, LDL-C decreased by 50.9% and apo-B by 55.6%, with an average pretreatment LDL-C level of 615 mg/dL.

    “Four weeks following commencement of a low-fat diet and administration of lomitapide in patients with hoFH, the blood LDL-C level and apo-B level decreased by 50.9% and 55.6%, respectively (average pretreatment LDL-C level: 615 mg/dL)684).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schoonjans, K., Staels, B., & Auwerx, J.
Affiliations
Inserm (FR)
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
1996-05
Volume
37
Issue
5
Pages
907-925
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2140038597
Cited by
1,216
References
198
Citations by year
2026: 9 · 2025: 18 · 2024: 9 · 2023: 14 · 2022: 21 · 2021: 21 · 2020: 27 · 2019: 22 · 2018: 31 · 2017: 35 · 2016: 32 · 2015: 43 · 2014: 34 · 2013: 42 · 2012: 32
FWCI
20.26
Type
journal article
Language
en
Open access
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
peroxisome proliferator-activated receptors, PPARα, PPARδ, PPARγ, fibrates, fatty acids, retinoid X receptor, peroxisome proliferator response element, HDL cholesterol, apolipoprotein A-I, apolipoprotein A-II, lipoprotein lipase, apolipoprotein C-III, fatty acid transporters, acyl-CoA synthetase, peroxisomal beta-oxidation, mitochondrial beta-oxidation, VLDL secretion, triglyceride-rich lipoproteins, hypotriglyceridemic effect, adipogenesis, thiazolidinediones, prostaglandin J2
MeSH terms
Animals, Hypolipidemic Agents, Cell Differentiation, Fatty Acids, Gene Expression Regulation, Humans, Transcription Factors, Adipocytes, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review